18 June 2020
The Gamaleya Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation will spend almost 16 million rubles to study a vaccine for the new coronavirus, and then test it on 60 volunteers.
According to the published data, the contractor will carry out the research work (R&D). The contract is valid from the moment the contract is signed until November 30th, 2020. However, there is a caveat that the work must be completed as soon as possible.
Under the terms of the contract, the performer is obliged to conclude insurance contracts for volunteers, prepare all necessary documentation for the study, purchase consumables, conduct clinical trials, and prepare a report for the Russian Ministry of Health on the results of the studies.
The study will be conducted in two stages, each with an equal number of volunteers of both sexes aged 18-60 years inclusive, a total of 60 people. Volunteers will be recruited from a group of 100 people previously surveyed. Participants will be monitored within 28 days of the vaccine being administered. After discharge from hospital, there will be another check-up on day 42.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024